Medicare Enrolled

Dr. Khusroo Qureshi, M.D.

Medical Oncology · Plano, TX
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Low-engagement
3705 W 15TH ST, Plano, TX 75075
9728673577
In practice since 2006 (19 years)
NPI: 1356380711 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Qureshi from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Qureshi? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Qureshi

Dr. Khusroo Qureshi is a medical oncology in Plano, TX, with 19 years in practice. Based on federal Medicare data, Dr. Qureshi performed 47,147 Medicare services across 1,968 unique beneficiaries.

Between the years covered by Open Payments, Dr. Qureshi received a total of $809 from 12 pharmaceutical and/or device companies across 41 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Qureshi is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 19 years in practice▲ Top 21% volume in TX$ $809 industry payments

Medicare Practice Summary

Medicare Utilization ↗
47,147
Medicare services
Top 21% in TX for medical oncology
1,968
Unique beneficiaries
$11
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~2,481 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

ProcedureVolumeAvg. paidAvg. submitted
Iron sucrose injection (Venofer)14,600$0$2
Darbepoetin injection (Aranesp) for anemia9,895$2$20
Pembrolizumab injection (Keytruda)5,000$43$137
Contrast dye for imaging (iodine-based)3,425$0$3
Paclitaxel chemotherapy injection3,218$0$8
Immune globulin infusion (Octagam)2,200$34$233
Denosumab injection (Prolia/Xgeva)1,500$18$65
Dexamethasone injection (steroid)1,187$0$1
Injection, granisetron hydrochloride, 100 mcg770$0$24
Blood draw (venipuncture)633$8$20
Complete blood count (CBC) with differential587$8$36
Comprehensive metabolic blood panel495$10$64
Office visit, established patient (30-39 min)375$93$368
Injection of additional new drug or substance into vein340$11$108
Anti-nausea injection (Aloxi/palonosetron)290$1$114
Ferritin level test (iron stores)276$13$60
Iron level test274$6$27
Iron binding capacity test274$9$35
Administration of chemotherapy into vein, 1 hour or less204$97$707
Office visit, established patient (20-29 min)164$67$250
Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less130$46$313
Drug injection, under skin or into muscle111$10$96
Injection, carboplatin, 50 mg89$2$300
Injection, diphenhydramine hcl, up to 50 mg77$1$7
Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less70$22$157
Reticulated (young) platelet measurement69$35$143
Unclassified drugs67$1$8
Administration of additional new drug or substance into vein, 1 hour or less66$49$344
Infusion, normal saline solution , 1000 cc66$2$19
Infusion into a vein for therapy, prevention, or diagnosis, each additional hour60$14$100
Administration of chemotherapy into vein, each additional hour59$21$161
Office visit, established patient, complex (40-54 min)57$133$496
Infusion into a vein for hydration, each additional hour42$10$75
Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle41$54$211
Hospital follow-up visit, moderate complexity35$61$247
Ct scan of chest with contrast33$49$821
Microscopic examination for white blood cells with manual cell count33$4$22
Complete blood count (CBC), automated33$6$34
CT scan of abdomen and pelvis with contrast32$171$1,067
Magnesium level test30$7$29
Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries29$91$657
Nuclear medicine study from skull base to mid-thigh with ct scan28$1,115$4,802
Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion28$15$94
Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle28$24$145
Lactate dehydrogenase (enzyme) level27$6$31
New patient office visit (45-59 min)21$127$565
Injection, fosnetupitant 235 mg and palonosetron 0.25 mg19$343$1,722
Drawing of blood for a medical problem18$73$264
Infusion into a vein for hydration, 31-60 minutes16$23$256
CT scan of chest, without contrast13$30$686
Ct scan of abdomen and pelvis without contrast13$81$560
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
5.5% high complexity
86.9% medium
7.6% routine

Industry Payment Transparency

Open Payments through 2024 ↗
$809
Total received (2020-2024)
Avg $202/year across 4 years
Bottom 27% in TX for medical oncology
12
Companies
41
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$709 (87.5%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$101 (12.5%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$233
2023
$297
2022
$203
2020
$77

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
Novartis Pharmaceuticals Corporation
$341
Pharmacyclics LLC, An AbbVie Company
$147
Merck Sharp & Dohme LLC
$80
Janssen Biotech, Inc.
$51
ABBVIE INC.
$44
E.R. Squibb & Sons, L.L.C.
$34
Acrotech Biopharma LLC
$24
Amgen Inc.
$23
GE HealthCare
$21
GENZYME CORPORATION
$16
Exelixis Inc.
$16
PFIZER INC.
$13
Top 3 companies account for 70.1% of total payments
Associated products mentioned in payments ›
BELEODAQ · Cabometyx · DARZALEX · ENJAYMO · EPKINLY · IBRANCE · IMBRUVICA · Imbruvica · KEYTRUDA · KISQALI · LUTATHERA · MEKINIST · Nplate · OPDIVO · PLUVICTO · VENCLEXTA
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

Most payments (88%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.

Equivalent to $2 per 100 Medicare services performed
Looking for a medical oncology in Plano?
Compare medical oncologys in the Plano area by procedure volume, costs, and industry payment transparency.
Browse medical oncologys nearby

Geographic Context

Medical Oncologys within 10 mi
75
Per 100K population
6.7
County median income
$117,588
Nearest hospital
MEDICAL CITY PLANO
0.0 mi

Data Sources

Provider Registry NPPESWeekly updates
Medicare Enrollment PECOSMonthly updates
Practice Data Medicare Util.Annual (CY lag)
Industry Payments Open PaymentsCY 2024
Disciplinary History— Not publicN/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →

Summary

Dr. Qureshi is a mixed practice specialist, with above-average Medicare volume (top 21% in TX), and low-engagement industry engagement, with 19 years of practice experience.

This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →

Frequently Asked Questions

Is Dr. Qureshi experienced with iron sucrose injection (venofer)?
Based on Medicare claims data, Dr. Qureshi performed 14,600 iron sucrose injection (venofer) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Qureshi receive payments from pharmaceutical companies?
Yes. Dr. Qureshi received a total of $809 from 12 companies across 41 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Qureshi's costs compare to other medical oncologys in Plano?
Dr. Qureshi's average Medicare payment per service is $11. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Qureshi) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →